NIKKEI 225
39,667.07 +493.92 (+1.26%) HANG SENG
18,089.93 +17.03 (+0.09%) CRUDE OIL
80.87 +0.04 (+0.05%) GOLD FUTURES
2,312.20 -18.60 (-0.80%) DOW
39,139.17 +27.01 (+0.07%) Bitcoin GBP
48,280.11 -788.88 (-1.61%)
Ionis Pharmaceuticals Inc (ISI.BE)
| Previous close | 42.16 |
| Open | 44.65 |
| Bid | 44.65 x 0 |
| Ask | 44.74 x 0 |
| Day's range | 44.65 - 44.65 |
| 52-week range | 33.35 - 48.58 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for olezarsen, an investigational RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS). The FDA has set an action date of December 19, 2024 and indicated they are not currently planning an advisory committee meeting for olezarsen.
- PR Newswire
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Ionis will maintain primary responsibility for the development of donidalorsen, while Otsuka will be responsible for territory-specific development, regulatory filings an
- PR Newswire
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.
